Statins and angiogenesis in non-cardiovascular diseases

Fatemeh Zahedipour; Alexandra E. Butler; Manfredi Rizzo; Amirhossein Sahebkar

doi:10.1016/j.drudis.2022.07.005

Statins and angiogenesis in non-cardiovascular diseases

Fatemeh Zahedipour, Alexandra E. Butler, Manfredi Rizzo, Amirhossein Sahebkar

UWA Medical School

Research output: Contribution to journal › Review article › peer-review

12 Citations (Web of Science)

Abstract

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.

Original language	English
Article number	103320
Journal	Drug Discovery Today
Volume	27
Issue number	10
DOIs	https://doi.org/10.1016/j.drudis.2022.07.005
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2022.07.005

Cite this

@article{bc24c085e6b0413a91fefcf804c75fa0,

title = "Statins and angiogenesis in non-cardiovascular diseases",

abstract = "Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.",

keywords = "Angiogenesis, Bone disease, Brain disease, Cancer, Cardiovascular, Diabetes, Ocular disease, Preeclampsia, Statins, Vascularization",

author = "Fatemeh Zahedipour and Butler, {Alexandra E.} and Manfredi Rizzo and Amirhossein Sahebkar",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = oct,

doi = "10.1016/j.drudis.2022.07.005",

language = "English",

volume = "27",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Statins and angiogenesis in non-cardiovascular diseases

AU - Zahedipour, Fatemeh

AU - Butler, Alexandra E.

AU - Rizzo, Manfredi

AU - Sahebkar, Amirhossein

PY - 2022/10

Y1 - 2022/10

N2 - Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.

AB - Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, cancer, preeclampsia, diabetes and bone disease, which are discussed in this review using reports from in vitro and in vivo investigations.

KW - Angiogenesis

KW - Bone disease

KW - Brain disease

KW - Cancer

KW - Cardiovascular

KW - Diabetes

KW - Ocular disease

KW - Preeclampsia

KW - Statins

KW - Vascularization

UR - http://www.scopus.com/inward/record.url?scp=85134851159&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2022.07.005

DO - 10.1016/j.drudis.2022.07.005

M3 - Review article

C2 - 35850434

AN - SCOPUS:85134851159

SN - 1359-6446

VL - 27

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 10

M1 - 103320

ER -

Statins and angiogenesis in non-cardiovascular diseases

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this